[{"orgOrder":0,"company":"PT. Daewoong Infion","sponsor":"Equilab International","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Human Erythropoietin Alpha","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"PT. Daewoong Infion","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PT. Daewoong Infion \/ Equilab International","highestDevelopmentStatusID":"1","companyTruncated":"PT. Daewoong Infion \/ Equilab International"},{"orgOrder":0,"company":"Renmin Hospital of Wuhan University","sponsor":"Wuhan Hamilton Biotechnology Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Renmin Hospital of Wuhan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Renmin Hospital of Wuhan University \/ Wuhan Hamilton Biotechnology Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Renmin Hospital of Wuhan University \/ Wuhan Hamilton Biotechnology Co., Ltd"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Canadian Institutes of Health Research","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arch Biopartners \/ Canadian Institutes of Health Research","highestDevelopmentStatusID":"1","companyTruncated":"Arch Biopartners \/ Canadian Institutes of Health Research"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BenevolentAI \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"BenevolentAI \/ AstraZeneca"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"University of Michigan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Walden Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Walden Biosciences \/ University of Michigan","highestDevelopmentStatusID":"1","companyTruncated":"Walden Biosciences \/ University of Michigan"},{"orgOrder":0,"company":"Taichung Veterans General Hospital","sponsor":"All Clean Health Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Low Protein Diet","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Taichung Veterans General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Taichung Veterans General Hospital \/ All Clean Health Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Taichung Veterans General Hospital \/ All Clean Health Co., Ltd"},{"orgOrder":0,"company":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","sponsor":"Morris Enterprise Co.,Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Eefooton","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation \/ Morris Enterprise Co.,Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation \/ Morris Enterprise Co.,Ltd."},{"orgOrder":0,"company":"Taichung Veterans General Hospital","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Low Protein Diet With Fresubin Renal","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Taichung Veterans General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taichung Veterans General Hospital \/ Fresenius Kabi AG","highestDevelopmentStatusID":"1","companyTruncated":"Taichung Veterans General Hospital \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"University of California, Irvine","sponsor":"VA Long Beach Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Plafond Diet","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"University of California, Irvine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Irvine \/ VA Long Beach Healthcare System","highestDevelopmentStatusID":"1","companyTruncated":"University of California, Irvine \/ VA Long Beach Healthcare System"},{"orgOrder":0,"company":"NIN Institute","sponsor":"Hospital Civil de Guadalajara","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Nutritious Shake","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"NIN Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Powder","sponsorNew":"NIN Institute \/ Hospital Civil de Guadalajara","highestDevelopmentStatusID":"1","companyTruncated":"NIN Institute \/ Hospital Civil de Guadalajara"},{"orgOrder":0,"company":"NIN Institute","sponsor":"Centro Medico Issemym","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"NIN Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIN Institute \/ Centro Medico Issemym","highestDevelopmentStatusID":"1","companyTruncated":"NIN Institute \/ Centro Medico Issemym"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Renalive Lp Vanilla","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Army Health Branch, British Army","sponsor":"University of East Anglia | Osteolabs, GEOMAR","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcium","moa":"Phosphate","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Army Health Branch, British Army","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Army Health Branch, British Army \/ University of East Anglia | Osteolabs, GEOMAR","highestDevelopmentStatusID":"1","companyTruncated":"Army Health Branch, British Army \/ University of East Anglia | Osteolabs, GEOMAR"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Apolipoprotein C-III mRNA 3'UTR","graph1":"Nephrology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Inapplicable"},{"orgOrder":0,"company":"University of Rochester School of Medicine & Dentistry","sponsor":"Evgen Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Sulforaphane","moa":"Inactive rhomboid protein 2 (RHBDF2)","graph1":"Nephrology","graph2":"Undisclosed","graph3":"University of Rochester School of Medicine & Dentistry","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Rochester School of Medicine & Dentistry \/ Evgen Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University of Rochester School of Medicine & Dentistry \/ Evgen Pharma"},{"orgOrder":0,"company":"University of Leicester","sponsor":"Loughborough University | YAKULT HONSHA CO LTD | Chinese University of Hong Kong | Universitaire Ziekenhuizen KU Leuven | Yakult Honsha European Research Center, ESV","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Yakult","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"University of Leicester","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Leicester \/ Loughborough University | YAKULT HONSHA CO LTD | Chinese University of Hong Kong | Universitaire Ziekenhuizen KU Leuven | Yakult Honsha European Research Center, ESV","highestDevelopmentStatusID":"1","companyTruncated":"University of Leicester \/ Loughborough University | YAKULT HONSHA CO LTD | Chinese University of Hong Kong | Universitaire Ziekenhuizen KU Leuven | Yakult Honsha European Research Center, ESV"},{"orgOrder":0,"company":"Taichung Veterans General Hospital","sponsor":"Grape King Bio Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Taichung Veterans General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taichung Veterans General Hospital \/ Grape King Bio Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Taichung Veterans General Hospital \/ Grape King Bio Ltd."},{"orgOrder":0,"company":"GenMont Biotech Incorporation","sponsor":"Chung Shan Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nephrology","graph2":"Undisclosed","graph3":"GenMont Biotech Incorporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenMont Biotech Incorporation \/ Chung Shan Medical University","highestDevelopmentStatusID":"1","companyTruncated":"GenMont Biotech Incorporation \/ Chung Shan Medical University"},{"orgOrder":0,"company":"QliniQ","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"QliniQ","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QliniQ \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"QliniQ \/ Hyloris Pharmaceuticals"},{"orgOrder":0,"company":"Lingli Dong","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PRG-1801","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Lingli Dong","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lingli Dong \/ Pregene","highestDevelopmentStatusID":"1","companyTruncated":"Lingli Dong \/ Pregene"},{"orgOrder":0,"company":"Kaohsiung Medical University Chung-Ho Memorial Hospital","sponsor":"TAIWAN KITOKU CO., LTD.","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Low Protein Rice Matsubumai","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Kaohsiung Medical University Chung-Ho Memorial Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaohsiung Medical University Chung-Ho Memorial Hospital \/ TAIWAN KITOKU CO., LTD.","highestDevelopmentStatusID":"1","companyTruncated":"Kaohsiung Medical University Chung-Ho Memorial Hospital \/ TAIWAN KITOKU CO., LTD."},{"orgOrder":0,"company":"Buddhist Tzu Chi General Hospital","sponsor":"Multipower Enterprise Corp.","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Boscogen","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Buddhist Tzu Chi General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Buddhist Tzu Chi General Hospital \/ Multipower Enterprise Corp.","highestDevelopmentStatusID":"1","companyTruncated":"Buddhist Tzu Chi General Hospital \/ Multipower Enterprise Corp."}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
Boscogen is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Kidney Failure, Chronic.
Details :
The new grant will help further understand the novel mechanism of action for DPEP-1 in kidney inflammation and its impact on CKD. Arch Biopartners is developing a pipeline of new candidates that inhibit inflammation in the lungs, liver, and kidneys via D...
Details :
Global rights of the ongoing development have been licensed-in from Dutch company, QliniQ, who maintains the rights to commercialize the product candidate in its home country, and a selected number of Middle Eastern and developing countries.
Reset All
